DaVita HealthCare Partners (NYSE:DVA) Director John M. Nehra unloaded 40,000 shares of DaVita HealthCare Partners stock on the open market in a transaction dated Friday, February 21st. The stock was sold at an average price of $65.81, for a total transaction of $2,632,400.00. Following the completion of the sale, the director now directly owns 81,766 shares in the company, valued at approximately $5,381,020. DaVita HealthCare Partners Inc. (NYSE:DVA) stock opened at $66.05 in last session, and closed at $67.50, while the day range of DaVita HealthCare Partners Inc. (NYSE:DVA) stock is $66.04 – $68.83. The stock showed a positive weekly performance of 1.70%.
Equities research analysts at Cowen and Company hoisted their price target on shares of Omnicare (NYSE:OCR) from $64.00 to $70.00 in a research note issued to investors on Thursday, American Banking & Market News reports. Cowen and Company’s target price would indicate a potential upside of 14.19% from the stock’s previous close. Omnicare, Inc. (NYSE:OCR) stock opened at $61.21 in last session, and closed at $59.91 by losing -2.27%. The 52 week range of $36.31 – $64.87. Company’s market capitalization is $6.02B.
MEDNAX, Inc., (NYSE:MD) announced the acquisition of Great Lakes Anesthesia Associates, P.C., a private practice physician group based in Grand Blanc, Mich. The practice, which was founded in 1993, will become part of MEDNAX’s American Anesthesiology division and is the second Michigan-based anesthesia practice to join the division. Mednax Inc. (NYSE:MD) stock increased 0.48% and finished the last session at $60.71. The EPS of the stock remained 2.78. Company’s market capitalization is $6.14B.
As of late, it has definitely been a great time to be an investor in BioTelemetry, Inc. (NASDAQ:BEAT). The stock has moved higher by 15.6% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favourable technical, could suggest that the stock may be on the right path. BioTelemetry, Inc. (NASDAQ:BEAT) stock opened the session at $9.96, and closed the session at $9.64. The 52 week range of the BioTelemetry, Inc. (NASDAQ:BEAT) stock remained $2.30 – $11.88 and the day range was $9.62 – $10.36.
Leave a Reply